Indigo Diabetes incorporates fully owned subsidiary in the US and appoints Peter J. Devlin as President, Indigo Medical US Inc.
27 October 2022
Indigo establishes a US presence to drive business development and extend talent acquisition
Peter brings over 30 years’ experience leading the development & commercialisation of medical devices, including devices for the diabetes market
Indigo Diabetes NV, a pioneering developer of Continuous Metabolite Monitoring (CMM™) devices utilising proprietary nanophotonics technology, today announces its expansion into the US via the incorporation of a fully owned subsidiary, Indigo Medical US Inc. and the appointment of Peter J. Devlin as President of the newly formed subsidiary, effective from 14 October 2022.
The Company is establishing its presence in the US, a market that it has identified as having significant potential for its CMM devices.
Peter, who will be based in Boston, will be managing and overseeing Indigo Medical’s activities. His focus will be on accelerating product development for the Company’s CMM devices, driving business development, and facilitating talent acquisition in the US. He will report directly to Danaë Delbeke, Chief Executive Officer of Indigo.
Indigo is developing a fully implantable CMM system for people living with diabetes to access accurate information on their glucose, ketones and lactate levels. The CMM sensor is inserted subcutaneously, preventing the need for people with diabetes to wear an external device on their body. It is designed to give people living with diabetes and their caregivers instant access to the augmented metabolic information they need to better manage their diabetes and improve therapeutic decision-making.
More information on Indigo's website.